November 10, 2025

Eli Lilly Strikes Multiple Deals for Ultra-Rare Eye Disease Gene Therapy and RNAi Partnerships

9 hours ago talkbio0Tagged AAV-AIPL4, eli lilly, gene therapy, Genetic Leap, Leber congenital amaurosis-4, MeiraGTx, Ophthalmology specialty, partnerships, RNA Interference, SanegeneBio

Eli Lilly; MeiraGTx; gene therapy; Leber congenital amaurosis-4; AAV-AIPL4; Genetic Leap; RNAi; SanegeneBio; ophthalmology; biotech partnerships

Ionis Claims Curative Potential for Tryngolza in Severe Triglyceride Disease

9 hours ago talkbio0Tagged Antisense Oligonucleotides, curative potential, Hypertriglyceridemia, Ionis, Pancreatitis, Acute, Phase 3 Clinical Trials, RNA-targeted therapy, Severe (severity modifier), Submission, Triglycerides, TRYNGOLZA, United States Food and Drug Administration

Ionis; Tryngolza; severe hypertriglyceridemia; curative potential; triglyceride reduction; acute pancreatitis; antisense oligonucleotide; FDA submission; Phase III trial; RNA-targeted therapy

Merck Reports Pivotal PCSK9 Pill Data in Race to Beat AstraZeneca to Market

9 hours ago talkbio0Tagged Approved, AstraZeneca, Autoimmune hemolytic anemia, Cardiovascular Diseases, CORALreef trial, enlicitide, LDL-C, Merck, oral cholesterol pill, PCSK9 inhibitor, United States Food and Drug Administration

Merck; PCSK9 inhibitor; enlicitide; oral cholesterol pill; AstraZeneca; CORALreef trial; LDL-C reduction; AHA 2025; FDA approval; cardiovascular disease

Amgen’s Repatha Reduces First-Time Cardiovascular Events by 25% in Major Clinical Trial

9 hours ago talkbio0Tagged amgen, Cardiovascular event, Cholesterol Drug, Clinical Trials, evolocumab, LDL Cholesterol Lipoproteins, Myocardial Infarction, PCSK9 inhibitor, Primary Prevention, Repatha, VESALIUS-CV

Amgen; Repatha; evolocumab; cholesterol drug; PCSK9 inhibitor; cardiovascular events; clinical trial; VESALIUS-CV; primary prevention; heart attack; LDL cholesterol

AstraZeneca Makes Strong Case for Baxdrostat with Detailed 24-Hour Data in Resistant Hypertension Trial

16 hours ago talkbio0Tagged 24-Hour Data, aldosterone synthase inhibitor, AstraZeneca, baxdrostat, Blood Pressure, blood pressure ambulatory, Phase 3 Clinical Trials, Resistant hypertensive disorder, safety profile

AstraZeneca; baxdrostat; resistant hypertension; phase III trial; aldosterone synthase inhibitor; blood pressure; 24-hour data; ambulatory blood pressure; safety profile

Pfizer Triumphs Over Novo Nordisk with $10B Bid to Acquire Metsera

17 hours ago talkbio0Tagged Acquisition, Approved, bidding war, Drug Industry, Glucagon-Like Peptide 1, Metsera, Nordisk, Obesity, Pfizer, shareholder

Pfizer; Novo Nordisk; Metsera; obesity drugs; GLP-1; acquisition; bidding war; shareholder approval; pharmaceutical industry

Eli Lilly Hires Denali Therapeutics Executive Carole Ho to Lead Neuroscience Division

17 hours ago talkbio0Tagged Biological Factors, Carole Ho, Changing, Denali, eli lilly, executive leadership, Leadership, neuroscience division

Eli Lilly; Denali Therapeutics; Carole Ho; neuroscience division; executive leadership; biopharmaceuticals; leadership changes

Vir Biotechnology’s Phase 2 Data for Hepatitis D Combo Regimen Highlights Market Potential

17 hours ago talkbio0Tagged Clinical Trials, Combined Modality Therapy, ECLIPSE program, elebsiran, HDV RNA, Hepatitis D Infection, Market, Phase 2, SOLSTICE, tobevibart, Undetectable, Vir Biotechnology

Vir Biotechnology; Phase 2; hepatitis D; combination therapy; tobevibart; elebsiran; SOLSTICE trial; undetectable HDV RNA; market potential; ECLIPSE program